The Experts below are selected from a list of 82308 Experts worldwide ranked by ideXlab platform
Francois Bissonnette - One of the best experts on this subject based on the ideXlab platform.
-
Substance P in Peritoneal fluid.
American Journal of Obstetrics and Gynecology, 2013Co-Authors: Joseph S. Sanfilippo, R. Stanford Williams, Christine L. Cook, Marvin A. Yussman, Francois BissonnetteAbstract:Substance P is a neuroPePtide that has been identified in the ovary, falloPian tube, uterus, and vagina and in the hyPothalamic-Pituitary axis in both an animal model and human ovaries. We sought to determine if Substance P is Present in Peritoneal fluid and, if so, whether it correlated with the cause of infertility. Its Presence was determined by radioimmunoassay in the Peritoneal fluid of 66 Patients undergoing diagnostic laParoscoPy for clinical indications related to infertility. Total volume of Peritoneal fluid and cycle day were recorded; Patients were evaluated in grouPs according to diagnosis: endometriosis ( n = 24), Pelvic adhesions ( n = 18), and normal controls ( n = 24). The level of Substance P (mean ± SEM) was 122 ± 19 Pg/ml for endometriosis and 130 ± 19 Pg/ml for Pelvic adhesions. These values were not significantly different from the normal controls (130 ± 25 Pg/ml). There was no significant difference in levels between follicular and luteal Phase of the menstrual cycle. We conclude that Substance P is Present normally in Peritoneal fluid and that its levels are not affected by Pelvic endometriosis or adhesions.
-
Substance P in Peritoneal fluid.
American Journal of Obstetrics and Gynecology, 2013Co-Authors: Joseph S. Sanfilippo, R. Stanford Williams, Christine L. Cook, Marvin A. Yussman, Francois BissonnetteAbstract:Substance P is a neuroPePtide that has been identified in the ovary, falloPian tube, uterus, and vagina and in the hyPothalamic-Pituitary axis in both an animal model and human ovaries. We sought to determine if Substance P is Present in Peritoneal fluid and, if so, whether it correlated with the cause of infertility. Its Presence was determined by radioimmunoassay in the Peritoneal fluid of 66 Patients undergoing diagnostic laParoscoPy for clinical indications related to infertility. Total volume of Peritoneal fluid and cycle day were recorded; Patients were evaluated in grouPs according to diagnosis: endometriosis ( n = 24), Pelvic adhesions ( n = 18), and normal controls ( n = 24). The level of Substance P (mean ± SEM) was 122 ± 19 Pg/ml for endometriosis and 130 ± 19 Pg/ml for Pelvic adhesions. These values were not significantly different from the normal controls (130 ± 25 Pg/ml). There was no significant difference in levels between follicular and luteal Phase of the menstrual cycle. We conclude that Substance P is Present normally in Peritoneal fluid and that its levels are not affected by Pelvic endometriosis or adhesions.
Ulla C. Kopp - One of the best experts on this subject based on the ideXlab platform.
-
CGRP Activates Renal Pelvic Substance P RecePtors by Retarding Substance P Metabolism
Hypertension, 1999Co-Authors: José R. Gontijo, Lori A. Smith, Ulla C. KoppAbstract:Abstract —Substance P and calcitonin gene–related PePtide (CGRP) are colocalized in renal Pelvic sensory nerves. Increasing renal Pelvic Pressure results in an increase in afferent renal nerve activity that is blocked by a Substance P recePtor antagonist but not by a CGRP recePtor antagonist. CGRP Potentiates the effects of Substance P by Preventing the metabolism of Substance P. Therefore, we examined whether CGRP enhanced the afferent renal nerve activity resPonses to Substance P and increased renal Pelvic Pressure, a stimulus known to increase Substance P release. Combined administration of Substance P and CGRP into the renal Pelvis resulted in an increase in afferent renal nerve activity (1392±217% · s; area under the curve of afferent renal nerve activity versus time) that was greater ( P P
Adina T. Michael-titus - One of the best experts on this subject based on the ideXlab platform.
-
Substance P fragments and striatal endogenous doPamine outflow: interaction with Substance P
Neuropeptides, 1998Co-Authors: Saima Khan, J Sandhu, Robin Whelpton, Adina T. Michael-titusAbstract:Abstract Accumulating evidence shows that N- and C-terminal Substance P fragments have significant biological activity. Substance P(1–9) and Substance P(6–11) have been rePorted to be major Substance P metabolites in rat striatum. We investigated the effects of these fragments on endogenous doPamine outflow in rat striatal slices. Substance P-(1–9) and Substance P-(6–11) induced a significant increase in doPamine outflow at 0.1 and 1 nM. The effects of Substance P-(6–11) (1 nM) were reversed by the tachykinin NK 1 antagonist WIN 51,708 (17β-hydroxy-17α-ethynyl-5α-androstano[3,2- b ]Pyrimido[1,2- a ]benzimidazole) (2.5 nM), whereas the effects of Substance P-(1–9) were not modified by the antagonist. Substance P-(1–9) and Substance P-(6–11) (1 nM) did not increase the doPamine overflow induced by 25 mM KCl. The effects of the two fragments were reversed by the muscarinic antagonist atroPine (1 μM) but not by nicotinic antagonists dihydro-β-erythroidine (0.5 μM) and PemPidine (10 μM). The co-incubation of tissue with Substance P and each fragment in a 1/1 or 10/1 ratio of Substance P to metabolite revealed a negative interaction between Parent and fragments. A similar Pattern was observed when Substance P was co-administered with the active fragments Substance P(1–4), Substance P(1–7), Substance P(5–11) and Substance P(8–11). The data show that Substance P-(1–9) and Substance P-(6–11) have modulatory effects similar to Substance P. However, the Presence of active Substance P metabolites does not aPPear to amPlify the signal mediated by the Parent PePtide.
-
Substance P-(1–7) and Substance P-(5–11) locally modulate doPamine release in rat striatum
European journal of pharmacology, 1995Co-Authors: Saima Khan, Robin Whelpton, Nicholas Brooks, Adina T. Michael-titusAbstract:Abstract The effects of Substance P, Substance P-(1–7) and Substance P-(5–11) on endogenous doPamine outflow in rat striatal slices were investigated. The dose-resPonse curves (0.01 nM to 10 μM) were bell-shaPed, with significant increases at 0.1 and 1 nM but with no effect at higher concentrations. The tachykinin NK1 recePtor agonist, [Sar9,Met(O2)11]Substance P, significantly increased doPamine outflow at 10 and 100 nM. The effects of Substance P or Substance P-(5–11) and 25 mM KCl were additive. A negative interaction was observed with Substance P-(1–7) and K+. The increase in doPamine outflow elicited by 1 nM Substance P and Substance P-(5–11) was reversed by the tachykinin NK1 recePtor antagonist WIN 51,708 (17β-hydroxy-17α-ethynyl-5α-androstano[3,2-b]Pyrimido[1,2-a]benzimidazole) (25 and 250 nM), whereas only Partial reversal was observed for the effect of Substance P-(1–7). These results show that Substance P fragments locally modulate striatal doPamine outflow and the mechanisms underlying this modulation may differ between N-and C-terminal fragments.
Joseph S. Sanfilippo - One of the best experts on this subject based on the ideXlab platform.
-
Substance P in Peritoneal fluid.
American Journal of Obstetrics and Gynecology, 2013Co-Authors: Joseph S. Sanfilippo, R. Stanford Williams, Christine L. Cook, Marvin A. Yussman, Francois BissonnetteAbstract:Substance P is a neuroPePtide that has been identified in the ovary, falloPian tube, uterus, and vagina and in the hyPothalamic-Pituitary axis in both an animal model and human ovaries. We sought to determine if Substance P is Present in Peritoneal fluid and, if so, whether it correlated with the cause of infertility. Its Presence was determined by radioimmunoassay in the Peritoneal fluid of 66 Patients undergoing diagnostic laParoscoPy for clinical indications related to infertility. Total volume of Peritoneal fluid and cycle day were recorded; Patients were evaluated in grouPs according to diagnosis: endometriosis ( n = 24), Pelvic adhesions ( n = 18), and normal controls ( n = 24). The level of Substance P (mean ± SEM) was 122 ± 19 Pg/ml for endometriosis and 130 ± 19 Pg/ml for Pelvic adhesions. These values were not significantly different from the normal controls (130 ± 25 Pg/ml). There was no significant difference in levels between follicular and luteal Phase of the menstrual cycle. We conclude that Substance P is Present normally in Peritoneal fluid and that its levels are not affected by Pelvic endometriosis or adhesions.
-
Substance P in Peritoneal fluid.
American Journal of Obstetrics and Gynecology, 2013Co-Authors: Joseph S. Sanfilippo, R. Stanford Williams, Christine L. Cook, Marvin A. Yussman, Francois BissonnetteAbstract:Substance P is a neuroPePtide that has been identified in the ovary, falloPian tube, uterus, and vagina and in the hyPothalamic-Pituitary axis in both an animal model and human ovaries. We sought to determine if Substance P is Present in Peritoneal fluid and, if so, whether it correlated with the cause of infertility. Its Presence was determined by radioimmunoassay in the Peritoneal fluid of 66 Patients undergoing diagnostic laParoscoPy for clinical indications related to infertility. Total volume of Peritoneal fluid and cycle day were recorded; Patients were evaluated in grouPs according to diagnosis: endometriosis ( n = 24), Pelvic adhesions ( n = 18), and normal controls ( n = 24). The level of Substance P (mean ± SEM) was 122 ± 19 Pg/ml for endometriosis and 130 ± 19 Pg/ml for Pelvic adhesions. These values were not significantly different from the normal controls (130 ± 25 Pg/ml). There was no significant difference in levels between follicular and luteal Phase of the menstrual cycle. We conclude that Substance P is Present normally in Peritoneal fluid and that its levels are not affected by Pelvic endometriosis or adhesions.
José R. Gontijo - One of the best experts on this subject based on the ideXlab platform.
-
CGRP Activates Renal Pelvic Substance P RecePtors by Retarding Substance P Metabolism
Hypertension, 1999Co-Authors: José R. Gontijo, Lori A. Smith, Ulla C. KoppAbstract:Abstract —Substance P and calcitonin gene–related PePtide (CGRP) are colocalized in renal Pelvic sensory nerves. Increasing renal Pelvic Pressure results in an increase in afferent renal nerve activity that is blocked by a Substance P recePtor antagonist but not by a CGRP recePtor antagonist. CGRP Potentiates the effects of Substance P by Preventing the metabolism of Substance P. Therefore, we examined whether CGRP enhanced the afferent renal nerve activity resPonses to Substance P and increased renal Pelvic Pressure, a stimulus known to increase Substance P release. Combined administration of Substance P and CGRP into the renal Pelvis resulted in an increase in afferent renal nerve activity (1392±217% · s; area under the curve of afferent renal nerve activity versus time) that was greater ( P P